Compare Meta Platforms Inc (META) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Meta Platforms Inc trades at $724.09 (market cap $1.84T), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Meta Platforms Inc is far larger — about 31.6× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| META | TAK | |
|---|---|---|
Market Cap | $1.84T | $58.16B |
Volume | 12,743,601 | 2,467,530 |
Sector | Media | Health |
52-Week High | $777.59 | $19.05 |
52-Week Low | $525.72 | $13.23 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $1.86T | $86.04B |
Dividend Yield | 0.29% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $720.89, down 2.43% on the day, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.8% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B partnership with CoreWeave highlight growth initiatives. Analyst consensus remains strongly bullish with 80% buy ratings and a $781 price target.
Meta presents a compelling investment case with strong profitability metrics and AI-driven growth potential, though faces regulatory risks from ongoing litigation and significant capital expenditure requirements. The stock's current valuation at 27x P/E appears reasonable given growth prospects, but investors should monitor execution on AI monetization and legal developments that could impact future earnings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
